0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > ErbB4

ErbB4

Brief Information

Name:Receptor protein-tyrosine kinase erbB-4
Target Synonym:ERBB4,Tyrosine kinase-type cell surface receptor HER4,s80HER4,p180erbB4,Receptor tyrosine-protein kinase erbB-4,4ICD,E4ICD,HER4,Erb-B2 Receptor Tyrosine Kinase 4,V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 4,Human Epidermal Growth Factor
Number of Launched Drugs:4
Number of Drugs in Clinical Trials:9
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
ER4-H5251 Human Human ErbB4 / Her4 Protein, Fc Tag
ER4-H5251-structure
ER4-H5251-sds
ER4-H5251-elisa_1
ER4-H5221 Human Human ErbB4 / Her4 Protein, His Tag
ER4-H5221-structure
ER4-H5221-sds
ER4-H5221-elisa_1

Part of Bioactivity data

ER4-H5221-ELISA
Human ErbB4, His TagHuman ErbB4, His Tag (Cat. No. ER4-H5221) ELISA bioactivity

Immobilized Human ErbB4, His Tag (Cat. No. ER4-H5221) at 2 μg/mL (100 μL/well) can bind Human NRG1 Beta 1, Fc Tag (Cat. No. NR1-H5268) with a linear range of 0.5-8 ng/mL (QC tested).

ER4-H5251-ELISA
Human ErbB4, Fc TagHuman ErbB4, Fc Tag (Cat. No. ER4-H5251) ELISA bioactivity

Immobilized Human ErbB4, Fc Tag (Cat. No. ER4-H5251) at 2 μg/mL (100 μL/well) can bind Human NRG1-beta 1 Protein with a linear range of 0.6-10 ng/mL (Routinely tested).

Synonym Name

HER4,ErbB4,MGC138404,p180erbB4

Background

Receptor tyrosine-protein kinase erbB-4 (ErbB4), also known as Her4, is a single-pass type I transmembrane glycoprotein that is a member of the ErbB family of tyrosine kinase receptors. ErbB family members serve as receptors for the epidermal growth factor (EGF) family of growth factors. ErbB4 is expressed in normal skeletal muscle, heart, pituitary, brain and several breast carcinomas. ERBB4 contains multiple furin-like cysteine rich domains, a tyrosine kinase domain, a phosphotidylinositol-3 kinase binding site and a PDZ domain binding motif. The protein binds to and is activated by neuregulins-2 and -3, heparin-binding EGF-like growth factor and betacellulin. Ligand binding induces a variety of cellular responses including mitogenesis and differentiation. Multiple proteolytic events allow for the release of a cytoplasmic fragment and an extracellular fragment. ErbB4 appears to play important roles in neuronal development, development of the heart and cancer. ERBB4 has been shown to interact with: DLG4, NRG1, STAT5A, and YAP1. Mutations in this gene have been associated with cancer. Other single-nucleotide polymorphisms and a risk haplotype have been linked to schizophrenia.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Dacomitinib PF-299; PF-804; PF-299804; PF-00299804; PF-00299804-3; PF-00299804-03 Approved Pfizer Inc Vizimpro Mainland China Carcinoma, Non-Small-Cell Lung Pfizer Europe Ma Eeig 2018-09-27 Solid tumours; Head and Neck Neoplasms; Neoplasms; Liver Diseases; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis Details
Neratinib Maleate PB-272; HKI-272; CAN-030; PF-0528767; WAY-179272 Approved Pfizer Pharmaceuticals Ltd (China) Nerlynx Mainland China Breast Neoplasms Excella Gmbh & Co Kg 2017-07-17 Solid tumours; Breast Neoplasms; Hepatic Insufficiency; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Pyrotinib Maleate HTI-1001; SHR-1258; BLTN Approved Jiangsu Hengrui Medicine Co Ltd 艾瑞妮 Mainland China Breast Neoplasms Jiangsu Hengrui Medicine Co Ltd 2018-08-12 Biliary Tract Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Adenocarcinoma of Lung; Breast Neoplasms; Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Afatinib Dimaleate BIBW-2992; BIBW-2992-MA2 Approved C.H. Boehringer Sohn Ag & Co. Kg 吉泰瑞, Tovok, Giotrif, Gilotrif, Tomtovok Mainland China Carcinoma, Non-Small-Cell Lung Boehringer Ingelheim International Gmbh 2013-07-12 Head and Neck Neoplasms; Rhabdomyosarcoma; Renal Insufficiency; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Neuroectodermal Tumors; Liver Diseases; Endometriosis; Breast Neoplasms; Colorectal Neoplasms; Urologic Neoplasms; Carcinoma, Squamous Cell; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Tarloxotinib Bromide PR-610; TH-4000; SN-33999 Phase 2 Clinical Threshold Neoplasms; Carcinoma, Non-Small-Cell Lung Details
PB-357 PB-357 Phase 1 Clinical Pfizer Inc Neoplasms Details
Sirotinib Maleate XZP-5491 Phase 1 Clinical Shandong Xuanzhu Pharmaceutical Technology Co Ltd Stomach Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung Details
Tesevatinib KD-019; KD-020; XL-647; EXEL-7647 Phase 3 Clinical Exelixis Inc Glioblastoma; Breast Neoplasms; Brain Neoplasms; Polycystic Kidney, Autosomal Dominant; Brain metastases; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Polycystic Kidney, Autosomal Recessive Details
Pirotinib Hydrochloride KBP-5209 Phase 2 Clinical Shandong Xuanzhu Pharmaceutical Technology Co Ltd Solid tumours; Breast Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
JRF-103 JRF103; JRF-103 Phase 2 Clinical Shenzhen Jinrui Foundation Biotechnology Co Ltd Solid tumours Details
Allitinib Tosylate AST-6; ALS-1306; AST-1306 Phase 2 Clinical Shanghai Allist Pharmaceutical Technology Co Ltd Breast Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Poziotinib NOV1201; HM-78136; HM-78136B; NOV-120101 Phase 2 Clinical Hanmi Pharmaceutical Co Ltd Solid tumours; Head and Neck Neoplasms; Stomach Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Glioma; Carcinoma, Non-Small-Cell Lung Details
Larotinib Mesylate Z-650 Phase 3 Clinical Guangdong Dongyangguang Pharmaceutical Co Ltd Solid tumours; Esophageal Neoplasms; Pancreatic Neoplasms; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma Details
EO-1001 NT-113 Edison Pharmaceuticals Details

This web search service is supported by Google Inc.

totop